Photo by Go Nakamura/Getty Images
A coalition of more than 100 healthcare stakeholders released a report this week outlining policy and regulatory recommendations to improve the country s response to future health crises.
The collaboration, which was convened by the Health Leadership Council and the Duke-Margolis Center for Health Policy, included private-sector, nonprofit and government organizations.
Its report focused on actions that could be taken to improve data and evidence generation; strengthen innovation and supply chain readiness; and innovate care delivery approaches. In each area, the report outlines key actions private sector leaders can commit to accomplishing together and identifies recommended actions for public sector leaders to improve coordination and collaborations for public health emergencies, wrote the report authors.
The Healthcare Leadership Council issued the following news:
Experts from across healthcare have identified specific policy and regulatory recommendations to improve the nation s ability to prepare for and respond to future health crises. The recommendations are part of a new report released by the
Healthcare Leadership Council and
Duke-Margolis Center for Health Policy and result from collaboration with more than 100 private-sector, nonprofit, and government organizations and stakeholders to assess the response to COVID-19 and the nation s existing disaster preparedness infrastructure.
The recommendations include some temporary steps taken to address the COVID-19 pandemic, which have proven beneficial and should be made permanent going forward, the experts say. These include making it easier for public and private organizations to work in partnership, prioritizing supply chain readiness before crises arise, streamlining regulations that allow providers to practice medicine whe
Long-time Merck CEO Ken Frazier to retire
PTI
Washington |
Updated on
×
Among the four Black CEOs to head a Fortune 500 company in the US, Frazier took on Trump for his tacit support of white supremacists
Long-time Merck executive Ken Frazier, whose leadership helped bring the drugmaker one of the most lucrative medicines in history and who is one of the few remaining Black CEOs of a major corporation, is retiring.
Frazier, Merck’s CEO since early 2011 and an advocate for minority advancement who took on then-President Trump’s tacit support of white supremacists, will retire in July.
Frazier, 66, will be replaced by Rob Davis, the chief financial officer, the company said on Thursday as it announced quarterly financial results. Frazier will become executive chairman of the board during a transition period. The change comes just months after Dr. Dean Li took over as head of Merck’s research and development.
Linda A. Johnson
FILE - In this July 20, 2017 file photo, Ken Frazier, chairman and chief executive officer of Merck speaks, with President Donald Trump at left, during an event to announce a Merck, Pfizer, and Corning joint partnership to make glass containers for medication, in the Roosevelt Room of the White House, in Washington. Merck announced Thursday, Feb. 4, 2021, that Frazier, will retire on July 1. He will be replaced by Rob Davis, the chief financial officer. (AP Photo/Alex Brandon, File) February 04, 2021 - 12:45 PM
Longtime Merck executive Ken Frazier, whose leadership helped bring the drugmaker one of the most lucrative medicines in history and who is one of the few remaining Black CEOs of a major corporation, is retiring.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman
February 4, 2021 GMT
KENILWORTH, N.J. (BUSINESS WIRE) Feb 4, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021. Mr. Frazier will continue to serve on Merck’s board of directors as executive chairman, for a transition period to be determined by the board. The Merck board of directors has unanimously elected Robert M. Davis, Merck’s current executive vice president, global services and chief financial officer, as chief executive officer, as well as a member of the board, effective July 1, 2021. Mr. Davis will become president of Merck, effective April 1, 2021, at which time the company’s operating divisions Huma